{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-07b310-2026-11-12T15:52:16Z",
    "date": "2026-11-12T15:52:16Z",
    "ocid": "ocds-h6vhtk-07b310",
    "description": "This is a Direct Award Process C intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For avoidance of doubt, the provisions of the Public Contract Regulations 2015 and Procurement Act do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by midnight on Tuesday, 17 November 2026. The contract has not yet formally been awarded, this notice serves as an intention to award under PSR. Written Representation should be sent to: kevin.edwards@attain.co.uk The Decision Maker for this award was NHS Essex ICB Executive Committee based on the value and term of the contract. In accordance with Regulation 21 of the Health Care Services (Provider Selection Regime) Regulations 2023, a comprehensive conflicts of interest review was undertaken regarding the decision to utilise Direct Award Process C. No conflicts of interest were declared or identified by any of the designated award decision makers or individuals connected with the process.",
    "initiationType": "tender",
    "tender": {
        "id": "ACE-0052-2026-ESX",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "DAP C - Tier II Community Urology and Gynaecology services - 27-28",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "85110000",
            "description": "Hospital and related services"
        },
        "mainProcurementCategory": "services",
        "description": "The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard.",
        "lots": [
            {
                "id": "1",
                "description": "The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard. The providers have been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "The existing provider is satisfying the original contract and will likely satisfy the proposed contract to a sufficient standard",
                            "type": "quality",
                            "description": "100"
                        },
                        {
                            "type": "price",
                            "description": "100"
                        }
                    ]
                },
                "hasOptions": false,
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKH3"
                    }
                ],
                "deliveryLocation": {
                    "description": "Services to south west Essex Population"
                },
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_OUTSIDE_SCOPE",
                "description": "The procurement falls outside the scope of application of the directive"
            }
        ],
        "procurementMethodRationale": "This is a Direct Award Process C intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For avoidance of doubt, the provisions of the Public Contract Regulations 2015 and Procurement Act do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by midnight Tuesday, 17 November 2026. The contract has not yet formally been awarded, this notice serves as an intention to award under PSR. The Authority has undertaken an appropriate and proportionate review of declarations and is satisfied that effective arrangements are in place to identify and manage any actual, potential, or perceived conflicts of interest. Where relevant, mitigation measures have been applied to ensure that no conflict is capable of conferring any undue advantage or disadvantage. On this basis, the Authority is satisfied that no conflict of interest has adversely affected, or is capable of adversely affecting, the integrity of the procurement. The provider has been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023.",
        "amendments": [
            {
                "id": "1",
                "unstructuredChanges": [
                    {
                        "oldValue": {
                            "text": "The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard."
                        },
                        "newValue": {
                            "text": "Mayflower Healthcare Alliance are commissioned to provide community urology and gynaecology services across south west Essex only due to historic commissioning arrangements. The services are managed through a block contract arrangement. The Population Health Improvement Plan identifies that both services will need to undertake a full review in the second half of 2026/27. Whilst this review is ongoing, and subject to the outcome we intend to DAP C the contract for a further year to align with the PHIP priorities There are currently no alternative community provision for these services, therefore if this contract were to cease the activity would flow into MSEFT thereby increasing their demand. The service is built on strong a strong relationship with the Provider, due to the number of years the ICB has held a contract with them. There are no quality or commissioning concerns with the services being provided. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard."
                        },
                        "where": {
                            "section": "II",
                            "label": "1.4"
                        }
                    },
                    {
                        "oldValue": {
                            "text": "The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard. The providers have been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023."
                        },
                        "newValue": {
                            "text": "Mayflower Healthcare Alliance are commissioned to provide community urology and gynaecology services across south west Essex only due to historic commissioning arrangements. The services are managed through a block contract arrangement. The Population Health Improvement Plan identifies that both services will need to undertake a full review in the second half of 2026/27. Whilst this review is ongoing, and subject to the outcome we intend to DAP C the contract for a further year to align with the PHIP priorities There are currently no alternative community provision for these services, therefore if this contract were to cease the activity would flow into MSEFT thereby increasing their demand. The service is built on strong a strong relationship with the Provider, due to the number of years the ICB has held a contract with them. There are no quality or commissioning concerns with the services being provided. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard. The providers have been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality has the highest weighting and will remain a key priority throughout the length of the contract. The Provider will be expected to continue to deliver a high quality service, maintaining agreed standards and performance Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II community urology and gynaecology services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023."
                        },
                        "where": {
                            "section": "II",
                            "label": "2.4"
                        }
                    },
                    {
                        "oldValue": {
                            "text": "This is a Direct Award Process C intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For avoidance of doubt, the provisions of the Public Contract Regulations 2015 and Procurement Act do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by midnight Tuesday, 17 November 2026. The contract has not yet formally been awarded, this notice serves as an intention to award under PSR. The Authority has undertaken an appropriate and proportionate review of declarations and is satisfied that effective arrangements are in place to identify and manage any actual, potential, or perceived conflicts of interest. Where relevant, mitigation measures have been applied to ensure that no conflict is capable of conferring any undue advantage or disadvantage. On this basis, the Authority is satisfied that no conflict of interest has adversely affected, or is capable of adversely affecting, the integrity of the procurement. The provider has been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023."
                        },
                        "newValue": {
                            "text": "This is a Direct Award Process C intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For avoidance of doubt, the provisions of the Public Contract Regulations 2015 and Procurement Act do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by midnight Tuesday, 17 November 2026. The contract has not yet formally been awarded, this notice serves as an intention to award under PSR. The Authority has undertaken an appropriate and proportionate review of declarations and is satisfied that effective arrangements are in place to identify and manage any actual, potential, or perceived conflicts of interest. Where relevant, mitigation measures have been applied to ensure that no conflict is capable of conferring any undue advantage or disadvantage. On this basis, the Authority is satisfied that no conflict of interest has adversely affected, or is capable of adversely affecting, the integrity of the procurement. The provider has been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality has the highest weighting and will remain a key priority throughout the length of the contract. The Provider will be expected to continue to deliver a high quality service, maintaining agreed standards and performance Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II community urology and gynaecology services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023."
                        },
                        "where": {
                            "section": "IV",
                            "label": "1.1"
                        }
                    }
                ]
            }
        ]
    },
    "awards": [
        {
            "id": "104757-2026-1",
            "relatedLots": [
                "1"
            ],
            "title": "DAP C - Tier II Dermatology Services 27-28",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-COH-07665222",
                    "name": "Mayflower Healthcare Alliance"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-NHS-D7T5G",
            "name": "NHS Essex Integrated Care Board",
            "identifier": {
                "legalName": "NHS Essex Integrated Care Board",
                "id": "D7T5G",
                "scheme": "GB-NHS"
            },
            "address": {
                "streetAddress": "Seax House, Victoria Road South",
                "locality": "Chelmsford",
                "region": "UKH3",
                "postalCode": "CM1 1QH",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Kevin Edwards",
                "telephone": "+44 1268594350",
                "email": "kevin.edwards@attain.co.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.essex.icb.nhs",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            }
        },
        {
            "id": "GB-COH-07665222",
            "name": "Mayflower Healthcare Alliance",
            "identifier": {
                "legalName": "Mayflower Healthcare Alliance",
                "id": "07665222",
                "scheme": "GB-COH"
            },
            "address": {
                "streetAddress": "Heybridge House, Southend Road",
                "locality": "Billericay",
                "region": "UKH3",
                "postalCode": "CM11 2PL",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-182665",
            "name": "The Independent Patient Choice and Procurement Panel",
            "identifier": {
                "legalName": "The Independent Patient Choice and Procurement Panel"
            },
            "address": {
                "streetAddress": "NHS England, 7 and 8 Wellington Place",
                "locality": "Leeds",
                "postalCode": "LS1 4AP",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "england.choice@nhs.net"
            },
            "roles": [
                "reviewBody"
            ]
        },
        {
            "id": "GB-FTS-179607",
            "name": "NHS Essex Integrated Care Board",
            "identifier": {
                "legalName": "NHS Essex Integrated Care Board"
            },
            "address": {
                "streetAddress": "Seax House, Victoria Road South",
                "locality": "Chelmsford",
                "postalCode": "CM1 1QH",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "telephone": "+44 1268594350",
                "email": "kevin.edwards@attain.co.uk"
            },
            "roles": [
                "mediationBody",
                "reviewContactPoint"
            ]
        }
    ],
    "buyer": {
        "id": "GB-NHS-D7T5G",
        "name": "NHS Essex Integrated Care Board"
    },
    "contracts": [
        {
            "id": "104757-2026-1",
            "awardID": "104757-2026-1",
            "title": "DAP C - Tier II Dermatology Services 27-28",
            "status": "active",
            "value": {
                "amount": 819043,
                "currency": "GBP"
            },
            "dateSigned": "2026-10-26T00:00:00Z"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 1
            },
            {
                "id": "2",
                "measure": "foreignBidsFromEU",
                "relatedLot": "1",
                "value": 1
            },
            {
                "id": "3",
                "measure": "foreignBidsFromNonEU",
                "relatedLot": "1",
                "value": 1
            }
        ]
    },
    "language": "en"
}